
Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Adicet Bio, Inc. (ACET) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.34, with a market capitalisation of $90.81M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.01 to $17.44. This page covers its latest market performance, valuation, price trends and company information.
$90.81M | |
$8.78 | |
$515.20 | |
$2.13 | |
$8.51 | |
17.00 | |
100.53K | |
-- | |
$17.44 | |
$6.01 | |
-- | |
-- |
Adicet Bio, Inc. (ACET) is trading at $8.34 in pre-market trading as of 2026-09-16 09:58:00, down 1.94% ($0.17) from the previous close of $8.51
Pre-market trading shows how investors are pricing ACET before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Adicet Bio, Inc. (ACET) moved from $9.59 to $8.34, representing a decline of 13.03% ($1.25).
The stock traded between $7.91 and $9.97 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 151.76 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 20.4%
ACET is currently trading at $8.34, placing it 20.4% of the way from its 52-week low of $6.01 to its 52-week high of $17.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 102 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Adicet Bio, Inc. (ACET) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.